COGNITION THERAPEUTICS INC (CGTX) Stock News

USA - NASDAQ:CGTX - US19243B1026 - Common Stock

1.76 USD

+0.01 (+0.57%)

Last: 10/8/2025, 7:34:29 PM

1.7315 USD

-0.03 (-1.62%)

After Hours: 10/8/2025, 7:34:29 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CGTX Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Benzinga - Mentions: CCCC CHEK HSDT NAOV ...

12 Health Care Stocks Moving In Monday's Intraday Session

a month ago - By: The Motley Fool - Mentions: IPDN HILS MENS EQ

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

a month ago - By: Benzinga - Mentions: CVM TLX COO GLMD ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

2 months ago - By: The Motley Fool

Cognition (CGTX) Q2 Grant Income Jumps

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

3 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

3 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

3 months ago - By: Yahoo Finance - Mentions: UNIT

Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress